Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, CMS To Begin Collaborating On Drug Safety Data Collection In 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS Medical Innovation Task Force report says CMS will assist FDA in postmarketing drug surveillance. The collaboration also includes parallel reviews by the two agencies to minimize delays between marketing approval and reimbursement.

You may also be interested in...



E-Clinical Trials Standardization Is Goal Of Trans-HHS Tech Innovation Push

The standardization initiative is outlined by a task force consisting of NIH, CDC, FDA and CMS chiefs. The group also directs HHS to educate department officials in technology transfer policies – a project the task force believes can be accomplished in a “matter of months.”

E-Clinical Trials Standardization Is Goal Of Trans-HHS Tech Innovation Push

The standardization initiative is outlined by a task force consisting of NIH, CDC, FDA and CMS chiefs. The group also directs HHS to educate department officials in technology transfer policies – a project the task force believes can be accomplished in a “matter of months.”

CBER Pilot Seeks To Improve Use Of Electronic Datasets

Sponsors are asked to volunteer to evaluate tools used to analyze nonclincial and clinical electronic datasets. FDA expects to recommend detailed standards for the submission of animal and human data.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel